Table 4.
Retrospective studies on platinum-based chemotherapy in patients with resected homologous recombination-deficient PDAC
| Disease setting | Mutations | Design | Therapy line | Therapy | Number of pts. | mDFS | mOS | Reference |
| Resected |
Group 1: BRCA1/2 or PALB2
Group 2: ATM/ATR/ATRX Group 3: BAP1, BARD1, BRIP1, CHEK1/2, RAD50/51/51B or FANCA/C/D2/E/F/G/L |
Retrospective | Adjuvant | Platinum-containing Platinum-naïve |
Total: 377 HRD: 63 HRP: 314 |
n.a. | HRD+platinum (n=49): 4.53 y HRD-platinum (n=14): 1.8 y HRP+platinum (n=220): 2.96 y HRP-platinum (n=94): 3.09 y |
83 |
| Resected |
BRCA1
BRCA2 |
Retrospective | n.a. | n.a. | Total: 20 | 13 m | n.a. | 84 |
| Resected |
BRCA1
BRCA2 PALB2 |
Retrospective | Various | Platinum-containing Platinum-naïve |
Total: 96 HRD: 32 HRP: 64 |
HRD+perioperative platinum: 19.9 m HRP+perioperative platinum: 11.7 m |
HRD+perioperative platinum: not reached HRP+perioperative platinum: 23.1 m |
89 |
| Resected |
BRCA1 (n=4)
gBRCA2 (n=18) |
Retrospective | Adjuvant | Platinum-containing Platinum-naïve |
Total: 127 HRD: 22 HRP: 105 |
HRD+platinum (n=10): 31 m HRD-platinum (n=8): 17.8 m HRP+platinum: 33 m HRP-platinum: 28 m |
130 |
HRD, homologous recombination-deficient; HRP, homologous recombination-proficient; m, month; n.a., not applicable; pts., patients; y, year.